Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;18(1):38-47.
doi: 10.3201/eid1801.110784.

Accelerating control of pertussis in England and Wales

Affiliations

Accelerating control of pertussis in England and Wales

Helen Campbell et al. Emerg Infect Dis. 2012 Jan.

Abstract

Results of an accelerated pertussis vaccination schedule for infants introduced in 1990 in England and Wales were examined. Earlier scheduling and sustained high vaccine coverage resulted in fewer reported cases of pertussis among infants, reinforcing the World Health Organization drive for on-time completion of the infant vaccination schedule. As determined by using the screening method, the first dose of vaccine was 61.7% effective in infants <6 months of age, and effectiveness increased with subsequent doses. Three doses of a good whole-cell pertussis vaccine were 83.7% effective in children 10-16 years of age; a preschool booster vaccination further reduced pertussis incidence in children <10 years of age. As in other industrialized countries, surveillance data during 1998-2009 showed that pertussis in England and Wales mainly persists in young infants (i.e., <3 months of age), teenagers, and adults. Future vaccine program changes may be beneficial, but additional detail is required to inform such decisions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes to routine childhood pertussis immunization programs and notifications of pertussis disease (all ages) and vaccine coverage among children <2 years of age, England and Wales, 1940–2009. DTwP, diphtheria/tetanus/whole-cell pertussis vaccine; DTaP3, diphtheria/tetanus/3-component acellular pertussis vaccine; DTaP5, diphtheria/tetanus/5-component aP vaccine; DTaP3-Hib, diphtheria/tetanus/3-component acellular pertussis/Haemophilus influenzae type b vaccine; DTaP3-Hib-IPV, diphtheria/tetanus/3-component acellular pertussis/Haemophilus influenzae type b/inactivated polio vaccine; DTaP3-IPV, diphtheria/tetanus/3-component acellular pertussis/inactivated polio vaccine; DTaP5-IPV, diphtheria/tetanus/5-component acellular pertussis/inactivated polio vaccine.
Figure 2
Figure 2
Age-group distribution of case-patients <12 months of age in pertussis case-notification reports, by total case-patients (A) and proportion by age (B), England and Wales, 1983–2009. Red, <3 months of age; blue, 3–5 months of age; black, 6–11 months of age.
Figure 3
Figure 3
Pertussis disease notifications, laboratory confirmations, and hospital episodes in infants <3 months of age, England and Wales, 1998–2009.

References

    1. Miller E, Vurdien JE, White JM. The epidemiology of pertussis in England and Wales. Commun Dis Rep CDR Rev. 1992;2:R152–4. - PubMed
    1. Miller E. Overview of recent clinical trials of acellular pertussis vaccines. Biologicals. 1999;27:79–86. 10.1006/biol.1999.0184 - DOI - PubMed
    1. Andrews N, Stowe J, Wise L, Miller E. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom. Vaccine. 2010;28:7215–20. 10.1016/j.vaccine.2010.08.062 - DOI - PubMed
    1. Health Protection Agency. Vaccination coverage statistics for children aged up to five years in the United Kingdom: July to December 2009. Health Protection Report, vol 4, no 12; 2010 Mar 26 [cited 2011 May 10]. http://www.hpa.org.uk/hpr/archives/2010/hpr1210.pdf
    1. Fry NK, Tzivra O, Li YT, McNiff A, Doshi N, Maple PA, et al. Laboratory diagnosis of pertussis infections: the role of PCR and serology. J Med Microbiol. 2004;53:519–25. 10.1099/jmm.0.45624-0 - DOI - PubMed

Publication types

MeSH terms

Substances